These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 32885085)

  • 21. A randomized, placebo-controlled, double-blinded trial of duloxetine in the treatment of general fatigue in patients with chronic fatigue syndrome.
    Arnold LM; Blom TJ; Welge JA; Mariutto E; Heller A
    Psychosomatics; 2015; 56(3):242-53. PubMed ID: 25660434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study protocol for a randomised, double-blind, placebo-controlled clinical trial of duloxetine for the treatment and prevention of musculoskeletal pain: altering the transition from acute to chronic pain (ATTAC pain).
    Strauss DH; Santhanam DR; McLean SA; Beaudoin FL
    BMJ Open; 2019 Mar; 9(3):e025002. PubMed ID: 30842115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Syndrome of inappropriate antidiuretic hormone secretion: a story of duloxetine-induced hyponatraemia.
    Amoako AO; Brown C; Riley T
    BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25911354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dysosmia and dysgeusia associated with duloxetine.
    Yoshida K; Fukuchi T; Sugawara H
    BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29170185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Probable Association of an Attack of Bilateral Acute Angle-Closure Glaucoma With Duloxetine.
    Shifera AS; Leoncavallo A; Sherwood M
    Ann Pharmacother; 2014 Jul; 48(7):936-939. PubMed ID: 24732786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.
    Iyengar S; Webster AA; Hemrick-Luecke SK; Xu JY; Simmons RM
    J Pharmacol Exp Ther; 2004 Nov; 311(2):576-84. PubMed ID: 15254142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between body mass index and response to duloxetine for aromatase inhibitor-associated musculoskeletal symptoms in SWOG S1202.
    Henry NL; Unger JM; Till C; Schott AF; Crew KD; Lew DL; Fisch MJ; Moinpour CM; Wade JL; Hershman DL
    Cancer; 2019 Jun; 125(12):2123-2129. PubMed ID: 30861098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antihyperalgesic effect of duloxetine and amitriptyline in rats after peripheral nerve injury: Influence of descending noradrenergic plasticity.
    Hoshino H; Obata H; Saito S
    Neurosci Lett; 2015 Aug; 602():62-7. PubMed ID: 26135544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Duloxetine in treatment of anxiety symptoms associated with depression.
    Dunner DL; Goldstein DJ; Mallinckrodt C; Lu Y; Detke MJ
    Depress Anxiety; 2003; 18(2):53-61. PubMed ID: 12964171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Noradrenaline reuptake inhibition increases control of impulsive action by activating D
    Sasamori H; Ohmura Y; Yoshida T; Yoshioka M
    Eur J Pharmacol; 2019 Feb; 844():17-25. PubMed ID: 30503361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain.
    Bomholt SF; Mikkelsen JD; Blackburn-Munro G
    Neuropharmacology; 2005 Feb; 48(2):252-63. PubMed ID: 15695164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Milnacipran: serotonin-noradrenaline reuptake inhibitor approved for fibromyalgia may be a useful antidepressant.
    Keks NA; Hope J; Keogh S; Copolov DL
    Australas Psychiatry; 2018 Oct; 26(5):537-540. PubMed ID: 30198305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased chromogranin a and carcinoid syndrome-like symptoms in a patient treated with duloxetine.
    Karger S; Wiesner T; Kersting A; Braun M; Ebert T; Wurst U; Kratzsch J; Stumvoll M; Fasshauer M
    Endocr Pract; 2014 Nov; 20(11):e215-8. PubMed ID: 25100382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial.
    Upadhyaya HP; Arnold LM; Alaka K; Qiao M; Williams D; Mehta R
    Pediatr Rheumatol Online J; 2019 May; 17(1):27. PubMed ID: 31138224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A probable case of movement disorder (Tardive dyskinesia) due to duloxetine treatment.
    Yılmaz R; Üstün D; Tuncer Uzun S; Reisli R; Türk Ş
    Agri; 2018 Oct; 30(4):199-201. PubMed ID: 30403275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Self-Limited Kleptomania Symptoms as a Side Effect of Duloxetine.
    Miller CW; Gallagher KE
    Case Rep Psychiatry; 2016; 2016():5472492. PubMed ID: 28018697
    [No Abstract]   [Full Text] [Related]  

  • 37. Serotonin noradrenaline reuptake inhibitors: A new generation of treatment for anxiety disorders.
    Baldwin DS
    Int J Psychiatry Clin Pract; 2006; 10 Suppl 2():12-5. PubMed ID: 24921677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Visual hallucinations during duloxetine treatment in a patient with major depressive disorder.
    Tomita T; Yasui-Furukori N; Kaneko S
    Clin Neuropharmacol; 2013; 36(5):175-6. PubMed ID: 24045610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serotonin Syndrome From Duloxetine Monotherapy: A Case Report.
    Li L; Mi Q
    Cureus; 2023 Jun; 15(6):e40933. PubMed ID: 37496538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serotonin syndrome triggered by postoperative administration of serotonin noradrenaline reuptake inhibitor (SNRI).
    Takata J; Arashi T; Abe A; Arai S; Haruyama N
    JA Clin Rep; 2019 Aug; 5(1):55. PubMed ID: 32025920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.